Amneal Pharmaceuticals (AMRX) Capital Leases (2017 - 2026)

Amneal Pharmaceuticals' Capital Leases history runs 10 years deep, the most recent figure standing at $54.9 million for Q1 2026.

• On a quarterly basis, Capital Leases fell 3.05% year-over-year to $54.9 million in Q1 2026; TTM through Mar 2026 was $54.9 million, a 3.05% decrease from a year earlier, with the FY2025 full-year figure at $54.9 million, down 3.45% from the prior year.
• Capital Leases held at $54.9 million in Q1 2026 per AMRX's latest filing, from $54.9 million in the prior quarter.
• Across five years, Capital Leases topped out at $61.3 million in Q3 2022 and bottomed at $54.9 million in Q1 2026.
• The 5-year median for Capital Leases is $58.6 million (2023), against an average of $58.2 million.
• Across the five-year window, Capital Leases advanced 0.86% in 2022 and slipped 3.75% in 2025, its largest moves.
• Year by year, Capital Leases stood at $60.8 million in 2022, then slipped by 3.63% to $58.6 million in 2023, then decreased by 2.86% to $56.9 million in 2024, then decreased by 3.45% to $54.9 million in 2025, then fell by 0.09% to $54.9 million in 2026.
• Per Business Quant, the three latest AMRX Capital Leases figures stand at $54.9 million (Q1 2026), $54.9 million (Q4 2025), and $55.7 million (Q3 2025).